Ernexa Therapeutics
ERNA | NASDAQ
$1.69
+$0.01 (+0.60%)
At close: Nov 16, 2026, 4:00 PM ET
$1.68
-$0.01 (-0.59%)
After-hours:
Nov 16, 2026, 5:58 PM ET
+0.60%
(1D)No price chart data available for 1D timeframe.
Rating
30.2
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #792/1021 (Top 78%)
Key Statistics
Market Data
Market Cap $2.86M
1D Range
1.66 1.81
52W Range
1.66 37.75
Valuation (TTM)
PE -0.10
PB 0.66
EV/EBITDA 0.13
Valuation (NTM)
Forward PE N/A
Forward PEG 0.00
Price Target $0.00
Cash Flow
FCF Yield -480.6%
SBC Adj. FCF Yield -549.3%
SBC Impact -14.3%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y -149.8% |
-3.9%
Dil EPS 3Y | 5Y 110.9% |
47.1%
FCF 3Y | 5Y 13.3% |
17.7%
Returns
ROA -196.5%
ROE -332.1%
ROIC -271.2%
Financial Health
Net Cash
$5.27M
Current Ratio 2.57
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs)....
Sector Healthcare
Industry Biotechnology
Employees 5
IPO Date Aug 29, 1991
Website www.ernexatx.com
Fiscal Year January - December
Latest News
No news articles available yet.
Add to Watchlist
Select watchlists to add or remove ERNA